Shots:

• The agreement allows CF patients aged ≥2yrs.with two copies of F508del mutation in CFTR gene to access Orkambi (lumacaftor/ivacaftor) and CF patients aged ≥12yrs. with either two or one copy of F508del mutation and copy of one of the other 14 licensed mutations to access Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in England
• The collaboration also allows expanded access to Kalydeco (ivacaftor) in patients with R117H mutation aged ≥18mos. and with one of the nine licensed gating mutations aged≥ 12mos.
• The access agreement with NHS England is for all Vertex’s licensed CF therapies and any future indications of these therapies. Additionally- reimbursement agreement has been signed in Scotland- Australia and Spain

Click here to­ read full press release/ article 

 Ref: Vertex | Image: Vertex